Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 3
2011 1
2012 2
2013 2
2014 3
2015 4
2017 6
2018 4
2019 9
2020 14
2021 15
2022 5
2023 2
2024 4
2025 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and Management of Headache: A Review.
Robbins MS. Robbins MS. JAMA. 2021 May 11;325(18):1874-1885. doi: 10.1001/jama.2021.1640. JAMA. 2021. PMID: 33974014 Review.
Acute treatments with gepants, antagonists to receptors for the inflammatory neuropeptide calcitonin gene-related peptide, such as rimegepant or ubrogepant, can eliminate headache symptoms for 2 hours in 20% of patients but have adverse effects of nausea and dry mouth in 1% to 4% …
Acute treatments with gepants, antagonists to receptors for the inflammatory neuropeptide calcitonin gene-related peptide, such as rimegepan …
5-HT1F agonists.
Steel SJ. Steel SJ. Handb Clin Neurol. 2024;199:43-50. doi: 10.1016/B978-0-12-823357-3.00032-X. Handb Clin Neurol. 2024. PMID: 38307661 Review.
While the exact mechanism contributing to decreased symptoms of an acute migraine attack remains unclear, selective 5-HT1F agonists have demonstrated clinical efficacy with lasmiditan as the only approved medication from this class to date. Lasmidit …
While the exact mechanism contributing to decreased symptoms of an acute migraine attack remains unclear, selective 5-HT1F …
Acute Treatment of Migraine.
Burch R. Burch R. Continuum (Minneap Minn). 2024 Apr 1;30(2):344-363. doi: 10.1212/CON.0000000000001402. Continuum (Minneap Minn). 2024. PMID: 38568487 Review.
LATEST DEVELOPMENTS: Triptans, ergot derivatives, and nonsteroidal anti-inflammatory drugs have historically been the main acute treatments for migraine. The development of new classes of acute treatment, including the small-molecule calcitonin gene-related peptide recepto …
LATEST DEVELOPMENTS: Triptans, ergot derivatives, and nonsteroidal anti-inflammatory drugs have historically been the main acute treatments …
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. Ailani J, et al. Headache. 2021 Jul;61(7):1021-1039. doi: 10.1111/head.14153. Epub 2021 Jun 23. Headache. 2021. PMID: 34160823
OBJECTIVE: To incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults. BACKGROUND: The American Headache Society previously published a Consensus Stateme …
OBJECTIVE: To incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute …
Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis.
VanderPluym JH, Halker Singh RB, Urtecho M, Morrow AS, Nayfeh T, Torres Roldan VD, Farah MH, Hasan B, Saadi S, Shah S, Abd-Rabu R, Daraz L, Prokop LJ, Murad MH, Wang Z. VanderPluym JH, et al. JAMA. 2021 Jun 15;325(23):2357-2369. doi: 10.1001/jama.2021.7939. JAMA. 2021. PMID: 34128998 Free PMC article.
Compared with placebo, calcitonin gene-related peptide receptor antagonists (low to high SOE), lasmiditan (5-HT1F receptor agonist; high SOE), dihydroergotamine (moderate to high SOE), ergotamine plus caffeine (moderate SOE), acetaminophen (moderate SOE), ant …
Compared with placebo, calcitonin gene-related peptide receptor antagonists (low to high SOE), lasmiditan (5-HT1F recep …
The potential of lasmiditan in migraine.
Mecklenburg J, Raffaelli B, Neeb L, Sanchez Del Rio M, Reuter U. Mecklenburg J, et al. Ther Adv Neurol Disord. 2020 Oct 21;13:1756286420967847. doi: 10.1177/1756286420967847. eCollection 2020. Ther Adv Neurol Disord. 2020. PMID: 33403005 Free PMC article. Review.
The US Food and Drug Administration (FDA) has recently approved lasmiditan for the acute treatment of migraine in adults based on positive results of two pivotal phase III trials, which showed a significant difference to placebo in the proportion of patients achievi …
The US Food and Drug Administration (FDA) has recently approved lasmiditan for the acute treatment of migraine in adults based …
The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials.
Tfelt-Hansen PC, Olesen J. Tfelt-Hansen PC, et al. J Headache Pain. 2012 Jun;13(4):271-5. doi: 10.1007/s10194-012-0428-7. Epub 2012 Mar 20. J Headache Pain. 2012. PMID: 22430431 Free PMC article. Review.
Lasmiditan is a novel selective 5-HT(1F) receptor agonist. It is both scientifically and clinically relevant to review whether a 5-HT(1F) receptor agonist is effective in the acute treatment of migraine. ...Thus, migraine can be treated with a drug that has n …
Lasmiditan is a novel selective 5-HT(1F) receptor agonist. It is both scientifically and clinically relevant to review whether a 5-HT …
Lasmiditan ameliorates serotonergic itch in mice: Possible involvement of 5-HT1F receptors.
Afrooghe A, Ahmadi E, Babaei M, Soltani ZE, Elahi M, Shayan M, Jafari RM, Dehpour AR. Afrooghe A, et al. Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb;398(2):1535-1543. doi: 10.1007/s00210-024-03329-8. Epub 2024 Aug 8. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 39115558
We aimed to investigate the efficacy of Lasmiditan, a highly selective agonist of the 5-hydroxytryptamine 1F (5-HT1F) receptor and a recently approved medication for the treatment of migraine headaches, in ameliorating serotonergic itching. ...Followin …
We aimed to investigate the efficacy of Lasmiditan, a highly selective agonist of the 5-hydroxytryptamine 1F (5-HT1F) r …
Lasmiditan for acute treatment of migraine.
Parikh S. Parikh S. Drugs Today (Barc). 2021 Feb;57(2):89-100. doi: 10.1358/dot.2021.57.2.3238326. Drugs Today (Barc). 2021. PMID: 33656015 Review.
Lasmiditan, a selective 5-HT1F receptor agonist, is a harbinger for the novel ditan class of medications for acute migraine treatment. ...Notably, lasmiditan does not result in vasoconstriction, making lasmiditan a migraine-specifi …
Lasmiditan, a selective 5-HT1F receptor agonist, is a harbinger for the novel ditan class of medications for acute m …
The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine.
Reuter U, Israel H, Neeb L. Reuter U, et al. Ther Adv Neurol Disord. 2015 Jan;8(1):46-54. doi: 10.1177/1756285614562419. Ther Adv Neurol Disord. 2015. PMID: 25584073 Free PMC article. Review.
New drugs with a better adverse event profile and at least similar efficacy are needed for migraine subjects who cannot tolerate triptans for attack treatment. Lasmiditan is a novel highly specific 5-HT1F receptor agonist currently in clinical trials f …
New drugs with a better adverse event profile and at least similar efficacy are needed for migraine subjects who cannot tolerate trip …
71 results